Literature DB >> 10841804

Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents.

R F Borch1, J Liu, J P Schmidt, J T Marakovits, C Joswig, J J Gipp, R T Mulcahy.   

Abstract

A series of novel nitroheterocyclic phosphoramidates has been prepared, and the cytotoxicity of these compounds has been evaluated in clonogenic assays against B16, wild-type and cyclophosphamide-resistant MCF-7, and HT-29 cells under aerobic conditions and HT-29 cells under hypoxic conditions. All compounds were comparable in toxicity to wild-type and resistant MCF-7 cells and were also selectively toxic to HT-29 cells under hypoxic conditions (selectivity ratios 1.7 to >20). Analogues lacking the nitro group were not cytotoxic. Electron-withdrawing substituents increased cytotoxicity under aerobic conditions and thereby decreased hypoxic selectivity. In contrast, an electron-donating substituent markedly decreased both aerobic and hypoxic cytotoxicity but enhanced hypoxic selectivity. Chemical reduction of the nitro group resulted in rapid expulsion of the cytotoxic phosphoramide mustard. The most potent of these compounds show significant cytotoxicity under both aerobic and hypoxic conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10841804     DOI: 10.1021/jm0001020

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Bioreducible Phosphonoamidate Pro-drug Inhibitor of Enolase: Proof of Concept Study.

Authors:  Victoria C Yan; Kristine L Yang; Elliot S Ballato; Sunada Khadka; Prakriti Shrestha; Kenisha Arthur; Dimitra K Georgiou; Mykia Washington; Theresa Tran; Anton H Poral; Cong-Dat Pham; Matthew J Yan; Florian L Muller
Journal:  ACS Med Chem Lett       Date:  2020-06-22       Impact factor: 4.345

Review 2.  Why Great Mitotic Inhibitors Make Poor Cancer Drugs.

Authors:  Victoria C Yan; Hannah E Butterfield; Anton H Poral; Matthew J Yan; Kristine L Yang; Cong-Dat Pham; Florian L Muller
Journal:  Trends Cancer       Date:  2020-06-11

3.  Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing.

Authors:  Aurélien Voissiere; Elodie Jouberton; Elise Maubert; Françoise Degoul; Caroline Peyrode; Jean-Michel Chezal; Élisabeth Miot-Noirault
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

4.  An enolase inhibitor for the targeted treatment of ENO1-deleted cancers.

Authors:  Yu-Hsi Lin; Nikunj Satani; Naima Hammoudi; Victoria C Yan; Yasaman Barekatain; Sunada Khadka; Jeffrey J Ackroyd; Dimitra K Georgiou; Cong-Dat Pham; Kenisha Arthur; David Maxwell; Zhenghong Peng; Paul G Leonard; Barbara Czako; Federica Pisaneschi; Pijus Mandal; Yuting Sun; Rafal Zielinski; Susana Castro Pando; Xiaobo Wang; Theresa Tran; Quanyu Xu; Qi Wu; Yongying Jiang; Zhijun Kang; John M Asara; Waldemar Priebe; William Bornmann; Joseph R Marszalek; Ronald A DePinho; Florian L Muller
Journal:  Nat Metab       Date:  2020-11-23

5.  Nitroreductase-Mediated Release of Inhibitors of Lysine-Specific Demethylase 1 (LSD1) from Prodrugs in Transfected Acute Myeloid Leukaemia Cells.

Authors:  Eva-Maria Herrlinger; Mirjam Hau; Desiree Melanie Redhaber; Gabriele Greve; Dominica Willmann; Simon Steimle; Michael Müller; Michael Lübbert; Christoph Cornelius Miething; Roland Schüle; Manfred Jung
Journal:  Chembiochem       Date:  2020-04-27       Impact factor: 3.164

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.